Iovance Biotherapeutics, Inc.
US ˙ NasdaqGM ˙ US4622601007

Introduction

This page provides a comprehensive analysis of the known insider trading history of Ryan D Maynard. Insiders are officers, directors, or significant investors in a company. It is illegal for insiders to make trades in their companies based on specific, non-public information. This does not mean it is illegal for them to make any trades in their own companies. However, they must report all trades to the SEC via a Form 4. Despite these restrictions, academic research suggests that insiders - in general - tend to outperform the market in their own companies.

Average Trade Profitability

The average trade profitability is the average return of all the open market purchases made by the insider in the last three years. To calculate this, we examine every open-market, unplanned purchase made by the insider, excluding all trades that were marked as part of a 10b5-1 trading plan. We then calculate the average performance of those trades over 3, 6, and 12 months, averaging each of those durations to generate a final performance metric for each trade. Finally, we average all of the performance metrics to calculate a performance metric for the insider. This list only includes insiders that have made at least three trades in the last two years.

If this insiders trade profitability is "N/A", then the insider either has not made any open-market purchases in the last three years, or the trades they’ve made are too recent to calculate a reliable performance metric.

Update Frequency: Daily

See the list of most profitable insider traders.

Companies with Reported Insider Positions

The SEC filings indicate Ryan D Maynard has reported holdings or trades in the following companies:

Security Title Latest Reported Holdings
US:IOVA / Iovance Biotherapeutics, Inc. Director 7,500
US:CARA / Cara Therapeutics, Inc. CHIEF FINANCIAL OFFICER 8,012
US:RIGL / Rigel Pharmaceuticals, Inc. EVP & CFO 75,000
How to Interpret the Charts

The following charts show the stock performance of securities subsequent to each open-market, non-planned trade made by Ryan D Maynard. Non-planned trade are trades that were not made as part of a 10b5-1 trading plan. The stock performance is charted as cumulative percent change in share price. For example, if an insider trade was made on January 1, 2019, the chart will show the daily percent change of the security to the present day. If the share price were to go from $10 to $15 during this time, the cumulative percent change in share price would be 50%. A change in price from $10 to $20 would be 100%, and a change in price of $10 to $5 would be -50%.

Ultimately, we are trying to determine how closely the insider’s trades correlate to excess returns (positive or negative) in the share price in order to see if the insider is timing their trades to profit from insider information. Consider the situation where an insider was doing this. In this situation, we would expect either (a) positive returns after purchases, or (b) negative returns after sales. In the case of (a), the PURCHASE chart would show a series of upwardly sloping curves, indicating positive returns after each purchase transaction. In the case of (b), the SALE chart would show a series of downward sloping curves, indicating negative returns after each sale transaction.

However, this alone is not enough to draw conclusions. If, for example, the share price of the company was in a non-cyclical climb over many years, then we would expect all the post-purchase plots to be upwardly sloping. Likewise, non-cyclical declines over many years would result in downward sloping post-trade plots. Neither of these charts would suggest insider trading activity.

The strongest indicator would be a situation where the share price was extremely cyclical, and there were both positive signals in the PURCHASE chart and negative plots on the SALE chart. This situation would be highly suggestive of an insider that was timing trades to their financial advantage.

Insider Purchases IOVA / Iovance Biotherapeutics, Inc. - Short Term Profit Analysis

In this section, we analyze the profitability of every unplanned, open-market insider purchase made in IOVA / Iovance Biotherapeutics, Inc.. This analysis helps to understand if the insider consistently generates abnormal returns, and is worth following. This analysis is for one-year following each trade, and the results are theoretical.

The following table shows the most recent open market purchases that were not part of an automatic trading plan.

Trade Date Ticker Insider Reported
Shares
Reported
Price
Adjusted
Shares
Adjusted
Price
Cost Basis Days to
Max
Price at
Max
Max
Profit ($)
Max Return (%)
2022-05-31 IOVA Maynard Ryan D 7,500 6.7450 7,500 6.7450 50,588 77 13.0500 47,288 93.48

Adjusted Price is the split-adjusted price. Adjusted Shares is the split-adjusted shares.

IOVA / Iovance Biotherapeutics, Inc. Insider Trades
Insider Sales IOVA / Iovance Biotherapeutics, Inc. - Short Term Loss Analysis

In this section, we analyze the short-term loss avoidance of every unplanned, open-market insider sale made in IOVA / Iovance Biotherapeutics, Inc.. A consistent pattern of loss avoidance may suggest that future sale transactions may predict declines in price. This analysis is for one-year following each trade, and the results are theoretical.

The following table shows the most recent open market sales that were not part of an automatic trading plan.

Trade Date Ticker Insider Reported
Shares
Reported
Price
Adjusted
Shares
Adjusted
Price
Cost Basis Days to
Min
Price at
Min
Max Loss
Avoided ($)
Max Loss
Avoided (%)
2024-11-12 IOVA Maynard Ryan D 50,000 10.0600 50,000 10.0600 503,000 185 1.6600 -420,000 -83.50

Adjusted Price is the split-adjusted price. Adjusted Shares is the split-adjusted shares.

IOVA / Iovance Biotherapeutics, Inc. Insider Trades
Insider Purchases RIGL / Rigel Pharmaceuticals, Inc. - Short Term Profit Analysis

In this section, we analyze the profitability of every unplanned, open-market insider purchase made in IOVA / Iovance Biotherapeutics, Inc.. This analysis helps to understand if the insider consistently generates abnormal returns, and is worth following. This analysis is for one-year following each trade, and the results are theoretical.

The following table shows the most recent open market purchases that were not part of an automatic trading plan.

Trade Date Ticker Insider Reported
Shares
Reported
Price
Adjusted
Shares
Adjusted
Price
Cost Basis Days to
Max
Price at
Max
Max
Profit ($)
Max Return (%)
There are no known unplanned open-market trades for this insider and security combination

Adjusted Price is the split-adjusted price. Adjusted Shares is the split-adjusted shares.

RIGL / Rigel Pharmaceuticals, Inc. Insider Trades
Insider Sales RIGL / Rigel Pharmaceuticals, Inc. - Short Term Loss Analysis

In this section, we analyze the short-term loss avoidance of every unplanned, open-market insider sale made in IOVA / Iovance Biotherapeutics, Inc.. A consistent pattern of loss avoidance may suggest that future sale transactions may predict declines in price. This analysis is for one-year following each trade, and the results are theoretical.

The following table shows the most recent open market sales that were not part of an automatic trading plan.

Trade Date Ticker Insider Reported
Shares
Reported
Price
Adjusted
Shares
Adjusted
Price
Cost Basis Days to
Min
Price at
Min
Max Loss
Avoided ($)
Max Loss
Avoided (%)
2012-09-12 RIGL Maynard Ryan D 23,302 10.6669 2,330 106.6690 248,560 350 30.7 -177,029 -71.22
2012-09-10 RIGL Maynard Ryan D 17,586 10.5156 1,759 105.1560 184,927
2012-09-07 RIGL Maynard Ryan D 34,112 10.5523 3,411 105.5230 359,960
2012-08-07 RIGL Maynard Ryan D 700 10.6000 70 106.0000 7,420
2012-08-07 RIGL Maynard Ryan D 100 10.6100 10 106.1000 1,061
2012-08-07 RIGL Maynard Ryan D 600 10.6200 60 106.2000 6,372
2012-08-07 RIGL Maynard Ryan D 300 10.6250 30 106.2500 3,188

Adjusted Price is the split-adjusted price. Adjusted Shares is the split-adjusted shares.

RIGL / Rigel Pharmaceuticals, Inc. Insider Trades
Insider Trading History

This table shows the complete list of insider trades made by Ryan D Maynard as disclosed to the Securities Exchange Commission (SEC).

File Date Tran Date Form Ticker Security Code 10b5-1 Shares Remaining Shares Percent
Change
Share
Price
Tran
Value
Remaining
Value
2024-11-14 2024-11-12 4 IOVA IOVANCE BIOTHERAPEUTICS, INC.
Common Stock
S - Sale -50,000 7,500 -86.96 10.06 -503,000 75,450
2024-11-14 2024-11-12 4 IOVA IOVANCE BIOTHERAPEUTICS, INC.
Common Stock
M - Exercise 50,000 57,500 666.67 7.45 372,500 428,375
2024-02-12 2023-02-08 4 CARA Cara Therapeutics, Inc.
Common Stock
S - Sale X -5,488 8,012 -40.65 0.53 -2,909 4,246
2024-02-05 2024-02-01 4 CARA Cara Therapeutics, Inc.
Common Stock
A - Award 13,500 13,500
2022-06-02 2022-05-31 4 IOVA IOVANCE BIOTHERAPEUTICS, INC.
Common Stock
P - Purchase 7,500 7,500 6.74 50,588 50,588
2021-07-01 2021-06-29 4 IOVA IOVANCE BIOTHERAPEUTICS, INC.
Stock Option (right to buy)
A - Award 35,000 35,000
2020-06-10 2020-06-08 4 IOVA IOVANCE BIOTHERAPEUTICS, INC.
Stock Option (right to buy)
A - Award 35,000 35,000
2019-06-11 2019-06-10 4 IOVA IOVANCE BIOTHERAPEUTICS, INC.
Stock Option (right to buy)
A - Award 35,000 35,000
2018-07-19 2018-07-17 4 IOVA IOVANCE BIOTHERAPEUTICS, INC.
Stock Option (right to buy)
A - Award 35,000 35,000
2017-11-07 2017-11-03 4 RIGL RIGEL PHARMACEUTICALS INC
Employee Stock Option (right to buy)
M - Exercise -100,000 75,000 -57.14
2017-11-07 2017-11-03 4 RIGL RIGEL PHARMACEUTICALS INC
Common Stock
S - Sale X -100,000 0 -100.00 3.90 -390,000
2017-11-07 2017-11-03 4 RIGL RIGEL PHARMACEUTICALS INC
Common Stock
M - Exercise 100,000 100,000 2.14 214,000 214,000
2017-06-05 2017-06-01 4 LBIO Lion Biotechnologies, Inc.
Stock Option (right to buy)
A - Award 35,000 35,000
2017-04-21 2017-04-19 4 RIGL RIGEL PHARMACEUTICALS INC
Employee Stock Option (Right to Buy)
A - Award 150,000 150,000
2017-04-21 2017-04-19 4 RIGL RIGEL PHARMACEUTICALS INC
Employee Stock Option (Right to Buy)
A - Award 62,500 62,500
2017-02-06 2017-02-02 4 RIGL RIGEL PHARMACEUTICALS INC
Stock Option (Right to Buy)
A - Award 150,000 150,000
2016-08-18 2016-08-16 4 LBIO Lion Biotechnologies, Inc.
Stock Option (right to buy)
A - Award 35,000 35,000
2016-04-06 2016-04-04 4 RIGL RIGEL PHARMACEUTICALS INC
Employee Stock Option (right to buy)
A - Award 175,000 175,000
2016-04-06 2016-04-04 4 RIGL RIGEL PHARMACEUTICALS INC
Employee Stock Option (right to buy)
A - Award 62,500 62,500
2016-01-28 2016-01-26 4 RIGL RIGEL PHARMACEUTICALS INC
Stock Option (Right to Buy)
A - Award 150,000 150,000
2015-06-16 2015-06-12 4 LBIO Lion Biotechnologies, Inc.
Stock Option (right to buy)
A - Award 35,000 35,000
2015-02-17 2015-02-16 4 LBIO Lion Biotechnologies, Inc.
Stock Option (right to buy)
A - Award 50,000 50,000
2015-01-28 2015-01-26 4 RIGL RIGEL PHARMACEUTICALS INC
Stock Option (Right to Buy)
A - Award 175,000 175,000
2014-03-03 2014-02-27 4 RIGL RIGEL PHARMACEUTICALS INC
Stock Option (Right to Buy)
A - Award 125,000 125,000
2013-01-31 2013-01-30 4 RIGL RIGEL PHARMACEUTICALS INC
Stock Option (Right to Buy)
A - Award 150,000 150,000
2012-09-14 2012-09-12 4 RIGL RIGEL PHARMACEUTICALS INC
Stock Option (Right to Buy)
M - Exercise -23,302 73,300 -24.12
2012-09-14 2012-09-07 4 RIGL RIGEL PHARMACEUTICALS INC
Common Stock
S - Sale -23,302 0 -100.00 10.67 -248,560
2012-09-14 2012-09-07 4 RIGL RIGEL PHARMACEUTICALS INC
Common Stock
M - Exercise 23,302 23,302 6.49 151,230 151,230
2012-09-14 2012-09-12 4/A RIGL RIGEL PHARMACEUTICALS INC
Stock Option (Right to Buy)
M - Exercise -23,302 73,300 -24.12
2012-09-14 2012-09-12 4/A RIGL RIGEL PHARMACEUTICALS INC
Common Stock
S - Sale -23,302 0 -100.00 10.67 -248,560
2012-09-14 2012-09-12 4/A RIGL RIGEL PHARMACEUTICALS INC
Common Stock
M - Exercise 23,302 23,302 6.49 151,230 151,230
2012-09-11 2012-09-10 4 RIGL RIGEL PHARMACEUTICALS INC
Stock Option (Right to Buy)
M - Exercise -17,586 96,602 -15.40
2012-09-11 2012-09-10 4 RIGL RIGEL PHARMACEUTICALS INC
Common Stock
S - Sale -17,586 0 -100.00 10.52 -184,927
2012-09-11 2012-09-10 4 RIGL RIGEL PHARMACEUTICALS INC
Common Stock
M - Exercise 17,586 17,586 6.49 114,133 114,133
2012-09-11 2012-09-07 4 RIGL RIGEL PHARMACEUTICALS INC
Stock Option (Right to Buy)
M - Exercise -34,112 114,188 -23.00
2012-09-11 2012-09-07 4 RIGL RIGEL PHARMACEUTICALS INC
Common Stock
S - Sale -34,112 0 -100.00 10.55 -359,960
2012-09-11 2012-09-07 4 RIGL RIGEL PHARMACEUTICALS INC
Common Stock
M - Exercise 34,112 34,112 6.49 221,387 221,387
2012-08-09 2012-08-07 4 RIGL RIGEL PHARMACEUTICALS INC
Stock Option (Right to Buy)
M - Exercise -1,700 148,300 -1.13
2012-08-09 2012-08-07 4 RIGL RIGEL PHARMACEUTICALS INC
Common Stock
S - Sale -300 0 -100.00 10.62 -3,188
2012-08-09 2012-08-07 4 RIGL RIGEL PHARMACEUTICALS INC
Common Stock
S - Sale -600 300 -66.67 10.62 -6,372 3,186
2012-08-09 2012-08-07 4 RIGL RIGEL PHARMACEUTICALS INC
Common Stock
S - Sale -100 900 -10.00 10.61 -1,061 9,549
2012-08-09 2012-08-07 4 RIGL RIGEL PHARMACEUTICALS INC
Common Stock
S - Sale -700 1,000 -41.18 10.60 -7,420 10,600
2012-08-09 2012-08-07 4 RIGL RIGEL PHARMACEUTICALS INC
Common Stock
M - Exercise 1,700 1,700 6.49 11,033 11,033
2012-01-27 2012-01-25 4 RIGL RIGEL PHARMACEUTICALS INC
Stock Option (Right to Buy)
A - Award 150,000 150,000
P
Open market or private purchase of non-derivative or derivative security
S
Open market or private sale of non-derivative or derivative security
A
Grant, award, or other acquisition of securities from the company (such as an option)
C
Conversion of derivative
D
Sale or transfer of securities back to the company
F
Payment of exercise price or tax liability using portion of securities received from the company
G
Gift of securities by or to the insider
K
Equity swaps and similar hedging transactions
M
Exercise or conversion of derivative security received from the company (such as an option)
V
A transaction voluntarily reported on Form 4
J
Other (accompanied by a footnote describing the transaction)